Roth starts med tech focus list
Roth launched the focus list with “buy” rated AtriCure (NASDAQ:ATRC). Last week, Roth raised its target price on AtriCure to to $15 from $13.50, heading into the company’s FDA advisory panel meeting tomorrow. The stock closed at $10.16 on Monday.
“This list will be actively managed, such that ideas will be removed if our near-term thesis changes or the stock performs well, thereby altering the risk-reward profile of the strategy,” writes analyst Matt Dolan. “At times, the list will have several names and might be empty at others.”